Clinical Trials Browser

Phase 2 × Has announcements × selinexor × Clear all

NCT02227251 2025-10-01

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 2 Recruiting

244 enrolled 2 FDA

Lymphoma, Large B-Cell, Diffuse

NCT02336815 2023-01-26

STORM

Phase 2 Completed

202 enrolled 30 charts 1 FDA

Multiple Myeloma